Worst Now Behind It, Harvard Bio Ready for Turnaround At Restructured Genomic Solutions | GenomeWeb

Two years after its $26-million purchase of Genomic Solutions, Harvard Bioscience said last week that it can align the unit profitably with its operations.

“We believe we have taken the necessary steps to return Genomic Solutions to profitability on its current run rate of revenues,” Chane Graziano, the Holliston, Mass.-based company’s CEO, said in a conference call with analysts last week. “The worst is behind us.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.